Seteka Corporation contributes to the field of clinical diagnostics with its recombinant protein technology derived from silkworms.
Among new and re-emerging infectious diseases, it is important to develop IVD reagents to detect the spread of infection as early as possible and to raise awareness of infection prevention throughout society and among individuals.
In response to these problems, we aim to develop our genetically modified silkworm technology to expand our business in the field of IVDs.
Our technology enables the efficient production of antibodies and useful proteins within the silkworms, making mass production possible at reasonable cost.
Furthermore, this technology has attracted attention in developed countries from the perspective of animal welfare, and it is expected that its use will expand in the future.
Using this technology as a basis, we aim to collaborate with IVD manufacturers both in Japan and overseas to develop new recombinant antigens, monoclonal antibodies, and reagents in IVD field and to manufacture safe and stable products.
President & CEO
Munechika HASEGAWA
| Company Name | Seteka Corporation |
| Address Main Office | Shimada Bldg.,4-8-7, Roppongi, Minato-ku, Tokyo, 106-0032 |
| Kasumigaura Laboratory | 3F, 1103, Fukaya, Kasumigaura, Ibaraki Pref., 300-0134 |
| President | Munechika HASEGAWA |
| Founded | 2017/Feb/16 |
| Capital | 98 Mil Yen |
| Business Content | ・Development of Protein Production Using Genetically Modified Silkworms ・Contract Protein Expression Service Using Genetically Modified Silkworms ・Sales Business of Human-like Placenta ・Develepment Business of Cosmetic Ingredients |